Exciting news from Lipocine Inc.! The company has just unveiled a groundbreaking license and supply agreement for its innovative testosterone replacement therapy, TLANDO®, in Brazil. This strategic partnership is set to broaden access to this vital treatment across the Brazilian market, significantly boosting Lipocine’s presence on the global stage.
An Indian drugmaker, once under the microscope of ProPublica, has announced a recall of two dozen medications that were sent to patients across the U.S. This alarming development has sparked fresh concerns about the safety and quality of drugs, especially in light of previous investigations that uncovered troubling issues within the company.
Chiesi has invested €430 million in a new facility in Italy, aiming to bolster its production capabilities. Meanwhile, Bharat Biotech has inaugurated its first cell and gene therapy (CGT) site in India, marking a significant advancement in the region’s biopharmaceutical landscape.
SNBL and Tasso, Inc. have announced a strategic joint venture in Japan aimed at advancing innovative healthcare solutions. This collaboration is set to enhance patient accessibility to advanced diagnostic tools in the region, strengthening both companies’ market presence.
Eli Lilly is set to introduce its weight-loss drug in emerging markets this year, aiming to address rising obesity rates. The launch follows successful outcomes in developed regions, positioning Lilly to expand its global footprint in the competitive weight management sector.
A recent investigation by BBC reveals that an Indian pharmaceutical company is significantly contributing to West Africa’s escalating opioid crisis. The report highlights alarming practices, including the production and distribution of potent opioids, raising concerns about public health and regulatory oversight in the region.
